NEAL KLEIMAN to Cost-Benefit Analysis
This is a "connection" page, showing publications NEAL KLEIMAN has written about Cost-Benefit Analysis.
Connection Strength
0.048
-
Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery. J Thorac Cardiovasc Surg. 2018 05; 155(5):1991-1999.
Score: 0.029
-
Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Circulation. 2011 Aug 30; 124(9):1028-37.
Score: 0.019